CJC-1295 (No DAC) vs CJC-1295 DAC
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CJC-1295 DAC, CJC-1295 no DAC
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified GHRH(1-29), engineered for a long duration of action. The form most people mean by CJC-1295 includes a Drug Affinity Complex (DAC) that binds blood albumin to extend its half-life to roughly 6 to 8 days, raising GH and IGF-I for days from a single injection. It was developed by ConjuChem, reached Phase II trials and was abandoned; it is not an approved drug and is sold only as a research chemical. A version without DAC (Modified GRF 1-29) acts for only about 30 minutes.
Also: Modified GRF 1-29 DAC, Drug Affinity Complex CJC
CJC-1295 DAC is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH), built from a modified GRF(1-29) sequence with four amino acid swaps plus a Drug Affinity Complex (DAC) that lets it latch onto your own albumin after injection. That albumin trick stretches its half-life from minutes to roughly 6 to 8 days, so a single shot keeps nudging growth hormone and IGF-1 up for over a week. It is not FDA approved for any use; it was an investigational drug whose company development was halted, and today it circulates only as a research-grade or gray-market peptide.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | CJC-1295 (No DAC) | CJC-1295 DAC |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | CJC-1295 acts at the GHRH receptor on pituitary somatotroph cells, the same receptor the body's own GHRH uses, prompting the pituitary to synthesize and release growth hormone. Native GHRH is broken down within minutes; CJC-1295 with DAC carries a reactive group that covalently bonds to circulating albumin after injection, shielding it from breakdown and stretching its half-life from minutes to days. The sustained GH elevation drives the liver to produce IGF-I, the downstream hormone behind many of GH's tissue effects. There are two versions: with DAC (long-acting, albumin-binding) and without DAC (Modified GRF 1-29), which lacks the albumin tether. Because it works through the pituitary, it relies on the gland's own GH-producing capacity. | GHRH is the natural signal your hypothalamus sends to the pituitary to release growth hormone in pulses. CJC-1295 binds and activates the same GHRH receptor on the pituitary, prompting it to make and release more of its own growth hormone, which then raises IGF-1 from the liver. The four amino acid substitutions make it resist breakdown by the enzyme DPP-IV, and the DAC linker covalently bonds it to circulating albumin so it is not cleared quickly. Because it amplifies the body's own pulsatile signaling rather than injecting growth hormone directly, the effect is a sustained elevation rather than a single spike. |
| Common Dosing | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) | Limited community data available See research protocols |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks | 8-12 weeks typical |
| Best Time to Take | Before bed | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The key human study is Teichman et al. (2006) in the Journal of Clinical Endocrinology and Metabolism, a randomized, double-blind, placebo-controlled ascending-dose trial in healthy adults. A single subcutaneous injection raised mean plasma GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, with cumulative effects on repeat dosing, and was reported as safe and relatively well tolerated short-term. An earlier study showed once-daily CJC-1295 normalized growth in GHRH-knockout mice. Beyond pharmacokinetics and hormone levels, there are no large long-term human trials demonstrating clinical benefits like fat loss or muscle gain, so those claims are not established by published trials. Development was halted after Phase II; a single trial death was attributed by the attending physician to pre-existing coronary artery disease rather than the drug, which is reported but not independently confirmed. Bottom line: the GH and IGF-I-raising effect and long half-life are well supported, while real-world efficacy and long-term safety are not. | The core human evidence is a single early-phase study, Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2006, in healthy adults. A single subcutaneous dose raised GH roughly 2 to 10 fold and IGF-1 about 1.5 to 3 fold, with GH staying up for 6 days or more and IGF-1 elevated for 9 to 11 days, and repeated dosing kept IGF-1 above baseline for up to 28 days. The estimated half-life was about 5.8 to 8.1 days and no serious adverse reactions were reported in that short trial. Beyond that, the data is mostly animal work, such as a study showing once-daily CJC-1295 normalized growth in GHRH knockout mice. Importantly, clinical development by the original sponsor (ConjuChem) was stopped, and a related long-acting analog program saw a Phase II lipodystrophy study halted after a participant death, although the attending physician attributed that death to pre-existing coronary disease rather than the drug. So the honest read is: short-term pharmacology in humans is documented, but there are no long-term safety or efficacy trials, no approval, and real questions about chronically elevating IGF-1. |
Frequently Asked Questions: CJC-1295 (No DAC) vs CJC-1295 DAC
What is the difference between CJC-1295 (No DAC) and CJC-1295 DAC?
CJC-1295 (No DAC) is a growth hormone peptide that cjc-1295 is a synthetic analog of growth hormone-releasing hormone (ghrh), specifically a modified ghrh(1-29), engineered for a long duration of action. the form most people mean by cjc-1295 includes a drug affinity complex (dac) that binds blood albumin to extend its half-life to roughly 6 to 8 days, raising gh and igf-i for days from a single injection. it was developed by conjuchem, reached phase ii trials and was abandoned; it is not an approved drug and is sold only as a research chemical. a version without dac (modified grf 1-29) acts for only about 30 minutes. CJC-1295 DAC is a growth hormone peptide that cjc-1295 dac is a synthetic, long-acting analog of growth hormone-releasing hormone (ghrh), built from a modified grf(1-29) sequence with four amino acid swaps plus a drug affinity complex (dac) that lets it latch onto your own albumin after injection. that albumin trick stretches its half-life from minutes to roughly 6 to 8 days, so a single shot keeps nudging growth hormone and igf-1 up for over a week. it is not fda approved for any use; it was an investigational drug whose company development was halted, and today it circulates only as a research-grade or gray-market peptide. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 (No DAC) or CJC-1295 DAC?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 (No DAC) is typically used for growth hormone purposes, while CJC-1295 DAC is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 (No DAC) and CJC-1295 DAC be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 (No DAC) and CJC-1295 DAC together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.